Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
about
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyEvolving treatment paradigms for chemotherapy-induced nausea and vomitingPotential therapeutic targets for neurokinin-1 receptor antagonists5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentSynthetic and natural antioxidants attenuate cisplatin-induced vomitingEffects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialUpdate and new trends in antiemetic therapy: the continuing need for novel therapies.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Netupitant PET imaging and ADME studies in humans.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Chemotherapy-induced nausea and vomiting #285.Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrewsCasopitant: a new warrior in the antiemetic crusade.Anti-emetic mechanisms of Zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlatesThe antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.Aprepitant--a novel NK1-receptor antagonist.Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Clinical practice guidelines on antiemetics in oncology.Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia.Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases.Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisPalonosetron as an anti-emetic and anti-nausea agent in oncology.Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrewControl of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimensAblation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological researchOndansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinolReceptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva).Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Tachykinin receptor antagonists in clinical trials.
P2860
Q26783177-84CB4EC2-E0C7-4C0D-A32C-730D5102A9F8Q27024463-8DB4D47A-8288-4D29-9832-E27F41941F5BQ28262693-717B035A-F292-4670-909E-E56187D5A978Q28269736-CE11537D-10BB-4134-AEF5-B99C590417FBQ30834914-46241032-ABEE-4599-B7DD-557D241595A3Q34011870-BDD4DB3B-BC35-4E3A-A8D5-BEC19EB61B66Q34143667-62B4A176-C8BB-4F57-9451-3B29CB14DF30Q34166946-F8F514C8-EB24-4114-86B4-E6AB826DEC32Q34377521-0A0B2D72-86FA-46BD-8DCE-28B600FCFEDBQ34512212-FFE3E686-F523-493E-8BA7-8489BB47DEF9Q34588516-9DEE1C96-5FF6-4FE0-B84B-F28BA17D67A9Q34719140-91EDD3B0-EEE7-471C-A746-B2D470657619Q34807270-C7E1F236-85B1-4037-BD4D-B54A1F3BF1A5Q34981239-EB50008D-4576-405C-9C52-317E701CB1FCQ35164623-39A6AF1F-0506-4FED-9378-B6FAA245F80AQ35454299-275E0EDC-94E8-408B-AF87-743C93C7DBFEQ35594000-F7A03CD1-27A9-44D4-978C-6AF62FC2744AQ35627742-A8E49F11-FB05-4816-A361-CB3FEC0D8EEAQ35779340-88A531B1-670E-4542-967A-1DEEAF0BDD5EQ35942314-A0D95CC0-E475-46CA-BCB7-56E2B93EB8B3Q35962019-4793915C-BCC2-4F35-80BE-AB05C354AA45Q36064834-44FDDB5B-4478-45BB-86EC-EEB8E6626A9CQ36334870-484502C7-22A2-4ACF-9634-FBEA3EF721E9Q36400372-65E44219-7964-4E4F-9952-69B997681FBCQ36415811-588A5014-5CF4-47B4-862D-CFB40C894039Q36429871-E5EF55F7-6715-4AFE-8362-77FFA9A39687Q36524349-87007737-00FB-4564-9A28-962DE39A28D7Q36663660-B8F5F8E0-3404-485A-BD44-C45B1CDACE97Q36673972-89E46B1E-066D-4D6B-90F0-B6EC7D0FCDAAQ36843470-6BCAE106-B981-40B8-987F-4626A7736D42Q37036977-C28507B5-D252-48C4-9BC9-A7109F90365DQ37101114-4ABCC5C9-54FE-411A-87F4-16B08FE5583FQ37139336-5180E353-41C2-458B-891B-ECED1A24ADC2Q37271198-80BD1079-218B-48D5-89B7-336F1553D884Q37315620-7800C66B-9AF3-4DE2-9CC1-BD2C9076855BQ37315965-1E742118-141B-4372-BC4E-C8E1A47F1F6AQ37397648-4F48424B-2F39-4A28-B5BE-8E99C01CA8B8Q37407809-191D0920-7AFB-41B8-9F0A-86441ECA9419Q37609798-AD17EB0D-7F7E-4C91-AC3D-86689F4682DBQ37638682-6646C1B8-C612-4787-B651-8F691373DD7F
P2860
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Differential involvement of ne ...... specific receptor antagonists.
@en
Differential involvement of ne ...... specific receptor antagonists.
@nl
type
label
Differential involvement of ne ...... specific receptor antagonists.
@en
Differential involvement of ne ...... specific receptor antagonists.
@nl
prefLabel
Differential involvement of ne ...... specific receptor antagonists.
@en
Differential involvement of ne ...... specific receptor antagonists.
@nl
P2093
P1476
Differential involvement of ne ...... specific receptor antagonists
@en
P2093
A D Carides
F D Tattersall
P J Hesketh
R Hargreaves
R J Naylor
S Van Belle
P304
P356
10.1016/S0959-8049(02)00674-3
P577
2003-05-01T00:00:00Z